
'I don't want my parents to bury another child': Friedreich’s Ataxia patients 'beg' HSE for drug
The HSE was against funding the potentially life-changing treatment, which costs €288,000 per patient per year.

The HSE was against funding the potentially life-changing treatment, which costs €288,000 per patient per year.